US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Aardvark Therapeutics (AARD): Peeking at the Prospectus of Another Obesity-Related IPO

Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

Eli Lilly's Weight Loss Revolution: Is It Edging Out Novo Nordisk?

LifeVantage Corporation: - Successful MindBody GLP-1 System Launch

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.</li>
<li>ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.</li>
<li>The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.</li>
</ul>


Metsera, Inc. is developing next-generation injectable and oral NuSH analog peptides for obesity treatment.
ARCH Venture Partners, Google Ventures and Softbank's Vision Fund are all existing investors in this IPO.
The company is seeking an IPO valuation nearing $2bn for the company with a Phase III product candidate.


Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation